TABLE 2.

2-years survival, 95% confidence intervals and log-rank test for EFS and OS for all variables analyzed, for the whole cohort of patients.

		n	EFS				OS
			2-year survival	95% CI		p-value	2-year survival	95% CI		p-value
	All patients	67	56.6	44.2	72.5	—	79.2	67.4	93.2	—
Type	1st CR	44	60.7	44.9	82.0	0.21	80.2	65.1	98.8	0.40
	Primary refractory	23	47.1	29.4	75.3		77.2	59.6	100.0
Gender	Female	29	44.0	27.0	71.4	0.023	76.2	59.1	98.3	0.50
	Male	38	66.6	51.4	86.3		82.2	67.0	100.0
Age at diagnosis	<4 years	42	73.3	60.9	88.2	0.013	78.3	63.6	96.4	0.26
	≥4 years	25	20.6	6.7	63.9		81.0	62.8	100.0
MYCN	Amplified	12	50.0	28.4	88.0	0.35	50.9	24.6	100.0	0.088
	Not amplified	54	58.5	44.8	76.5		85.7	74.1	99.0
Cycles	5 or less	14	40.0	20.2	79.2	0.12	92.9	80.3	100.0	0.55
	More than 5	53	63.1	49.9	79.7		72.1	56.2	92.4
Previous ASCT	No	54	54.2	40.1	73.2	0.28	84.1	72.2	97.9	0.81
	Yes	13	64.1	40.2	100.0		66.7	42.0	100.0
Previous RDT	No	27	58.6	37.3	91.9	0.55	91.2	80.2	100.0	0.65
	Yes	40	54.8	40.5	74.2		75.6	60.9	93.9
MRD	No	51	53.9	39.6	73.3	0.58	73.3	58.9	91.1	0.21
	Yes	16	64.6	43.6	95.8		100.0	100.0	100.0